Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
Immuneering | 8-K: Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 -
Immuneering | 8-K：Immuneering 公布 2023 年第四季度和全年财务业绩并提供业务更新-IMM-1-104 1/2a 阶段试验第 1 阶段的重点数据，预计于 2024 年 3 月发布-